Filing Details
- Accession Number:
- 0001209191-15-078403
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-11-04 16:15:09
- Reporting Period:
- 2015-11-02
- Filing Date:
- 2015-11-04
- Accepted Time:
- 2015-11-04 16:15:09
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1334365 | Yuchun Lee | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-11-02 | 1,334 | $57.27 | 1,750 | No | 4 | M | Direct | |
Common Stock | Disposition | 2015-11-02 | 100 | $123.64 | 1,650 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-11-02 | 525 | $125.93 | 1,125 | No | 4 | S | Direct | |
Common Stock | Disposition | 2015-11-02 | 500 | $126.98 | 625 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Disposition | 2015-11-02 | 1,334 | $0.00 | 1,334 | $57.27 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
26,000 | 2022-09-13 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
- Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $125.93 (range $125.38 to $126.19).
- Open market sales reported on this line occurred at a weighted average price of $126.98 (range $126.64 to $127.57).
- The option vests in 16 quarterly installments from 09/14/2012.